MEDICXI VENTURES MANAGEMENT JERSEY LTD
Q1 2023 Form 13-F

ST. HELIER
CIK 0001715579 · Institutional investment manager
Consolidated report · includes 1 manager since Q4 2022
$233.4M Reported Value Total

MEDICXI VENTURES MANAGEMENT (JERSEY) LIMITED reports under management (AUM).

Source: Form ADV filed * Note that certain holdings are exempt from Form 13-F reporting, so the AUM totals may be greater than the Form 13-F total.
Reported value
$233.4M
Quarter over quarter
-2.0%
Holdings
6
Top-10 concentration
100.0%

Filing Structure

Reports holdings for

  • Francesco De Rubertis (not a 13F filer in our records) · Q4 2019 – Q3 2022 · declared by one filing
  • Ollier Michele (not a 13F filer in our records) · File #028-19835 · Q2 2021 – Q4 2021 · declared by one filing
  • Kevin Stuart Johnson (not a 13F filer in our records) · Q4 2019 – Q4 2021 · declared by one filing
  • Michele Ollier (not a 13F filer in our records) · Q4 2019 – Q4 2021 · declared by one filing

Key People

Named on the latest Form 13-F filing — not necessarily an owner
Giles Johnstone-Scott
Director
Q4 2022
Q2 2023
Go to latest
Loading 13F Metrics

Q1 2023 13F filing summary

Period of report March 31, 2023
Filed April 27, 2023
Form 13F-HR
Reported value $233.4M
Positions 6
Change in reported value -2.0%
New positions 0
Exited positions 0
Position turnover 0.0%
Top-10 concentration 100.0%

13F filings by quarter

Quarter Positions Value
Q3 2026 13F
Filed Nov 2, 2026
 3 $126.7M
Q2 2026 13F
Filed Aug 4, 2026
 3 $177.4M
Q1 2026 13F
Filed Apr 21, 2026
 4 $981.8M
Q4 2025 13F
Filed Jan 23, 2026
 5 $835.0M
Q3 2025 13F
Filed Oct 17, 2025
 5 $744.4M
Q2 2025 13F
Filed Jul 8, 2025
 5 $427.3M
Q1 2025 13F
Filed Apr 11, 2025
 5 $437.7M
Q4 2024 13F
Filed Jan 23, 2025
 5 $529.0M
Q3 2024 13F
Filed Oct 15, 2024
 4 $528.9M
Q2 2024 13F
Filed Jul 16, 2024
 4 $335.3M
Q1 2024 13F
Filed Apr 15, 2024
 5 $449.2M
Q4 2023 13F
Filed Feb 1, 2024
 5 $296.2M
Q3 2023 13F
Filed Oct 18, 2023
 6 $313.2M
Q2 2023 13F
Filed Jul 19, 2023
 6 $356.9M
Q1 2023 13F
Filed Apr 27, 2023
 6 $233.4M
Q4 2022 13F
Filed Jan 31, 2023
 6 $238.1M
Q3 2022 13F
Filed Oct 25, 2022
 5 $240.2M
Q2 2022 13F
Filed Aug 3, 2022
 6 $240.8M
Q1 2022 13F
Filed May 12, 2022
 7 $369.1M
Q4 2021 13F
Filed Feb 3, 2022
 7 $399.6M

8 earlier quarters on file — choose one from the quarter menu above.

Top 6 holdings · Q1 2023

# Holding Reported value % of portfolio
1 CNTA CENTESSA PHARMACEUTICALS PLC $76.9M 32.93%
2 PCVX VAXCYTE INC $54.6M 23.4%
3 MRUS MERUS N V $29.4M 12.61%
4 AURA AURA BIOSCIENCES INC $28.2M 12.09%
5 NAMS NEWAMSTERDAM PHARMA COMPANY $26.5M 11.36%
6 PHAT PHATHOM PHARMACEUTICALS INC $17.7M 7.6%

Values as reported on the Q1 2023 Form 13F. Every position is in the holdings table below.

Loading Activities
Loading Sector Allocation
Crunching numbers
Loading Performance
Finding Potential New Buys
Building table
Loading SEC filing data
Loading Form 4 Filings
Loading 13D/G filings